Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Abstract Introduction Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial hypertension (PAH). Data regarding use of PAH-specific therapies in patients with PoPH are sparse as they are usually excluded from clinical trials. This analysis describes patie...

Full description

Bibliographic Details
Main Authors: Nick H. Kim, Kelly M. Chin, Vallerie V. McLaughlin, Hilary DuBrock, Ricardo Restrepo-Jaramillo, Zeenat Safdar, Gwen MacDonald, Nicolas Martin, Daniel Rosenberg, Maria Solonets, Richard Channick
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-01-01
Series:Pulmonary Therapy
Subjects:
Macitentan
Portopulmonary hypertension
Pulmonary arterial hypertension
Real-world evidence
Online Access:https://doi.org/10.1007/s41030-023-00251-x

Similar Items

Similar Items